NLP-Based Feedback to Improve Risk Comms and Informed Shared Decision Making

Launched by CEDARS-SINAI MEDICAL CENTER · Jun 27, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to improve communication between doctors and patients with prostate cancer using a system that analyzes conversations. It's specifically looking at how well this system can summarize important information from medical consultations for men who are newly diagnosed with prostate cancer. The study will include 20 patients and aims to provide both the patients and their doctors with the top five key points discussed during their appointments, covering topics like cancer outlook, life expectancy, and potential side effects from treatment, such as issues with urination or sexual function.

To participate in this study, men must be between the ages of 65 and 74 and need to be receiving their first treatment consultation for localized prostate cancer or considering a change in treatment. Participants will receive personalized feedback about their consultations two weeks after their appointments. This trial is currently recruiting participants and focuses on those who can read and write in English. It's important to note that the study does not include men under 18, those with severe communication difficulties, or those who have already received treatment for prostate cancer.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Men undergoing initial treatment consultation for clinically localized prostate cancer;
• • 2. Men with upgraded prostate cancer on active surveillance considering conversion to definitive local therapy.
• • 3. Cedars-Sinai patient.
• • 4. Ability to read and write in English.
• Exclusion Criteria:
• • 1. Under 18 years of age;
• • 2. Subjects with difficulty communicating or dementia;
• • 3. Non-English speakers, given that our NLP-based tools cannot be used with languages other than English;
• • 4. Men with locally advanced or metastatic prostate cancer;
• • 5. Men who have already been treated for clinically localized prostate cancer